[GMOs and production of pharmaceutical molecules].
Antibodies have long been recognized for their diagnostic and therapeutic potential. The rapidly increasing number of monoclonal antibodies approved for immunotherapy has paved the way to an even greater demand for antibody molecules. In order to satisfy this growing demand, alternative systems based on transgenic organisms are actively explored to increase the production capacity. In this paper, we will focus on transgenic plants as a promising large scale production and processing system.
Faye
Loïc
L
CNRS UMR 6037-IFRMP23, Université de Rouen, 76821 Mont St Aignan, France.
Lerouge
Patrice
P
Gomord
Véronique
V
D000911:Antibodies, Monoclonal; D006031:Glycosylation; D004364:Pharmaceutical Preparations; D030821:Plants, Genetically Modified; D011994:Recombinant Proteins
D000911:Antibodies, Monoclonal; D004364:Pharmaceutical Preparations; D011994:Recombinant Proteins